Abstract
Introduction: Dupilumab, the first FDA-approved treatment for eosinophilic esophagitis (EoE), lacks real-world data on use and effectiveness. Methods: We conducted a retrospective cohort study of 70 EoE patients prescribed dupilumab, comparing prescriber type, indication, follow-up, and response. Results: Indications varied with gastroenterologists commonly prescribing for treatment-refractory cases and allergists as first-line therapy. Endoscopic assessment was lacking in 25.9%, but those with follow-up showed high histologic remission (92.3% first-line, 85% prior treatment failure). Conclusion: Dupilumab demonstrates effectiveness across EoE severity, including milder disease without prior treatment failure. Improving follow-up and assessing cost-effectiveness will help clarify its role in the treatment algorithm.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
